TERT promoter mutations in sinonasal malignant melanoma: A study of 49 cases

Melanoma Research

Volumn 25, Issue 3, 2014, Pages 185-188

  Jangard, Mattias ^a,b   Zebary, Abdlsattar ^b   Ragnarsson Olding, Boel ^b   Hansson, Johan ^b  

^a KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

^b KAROLINSKA INSTITUTE   (Sweden)

Author keywords

Mutation; Sinonasal melanoma; TERT promoter

Indexed keywords

B RAF KINASE; FORMALDEHYDE; PARAFFIN; TELOMERASE REVERSE TRANSCRIPTASE; TELOMERASE; TERT PROTEIN, HUMAN; TUMOR PROTEIN;

ADULT; AGED; ARTICLE; CANCER CELL; CANCER TISSUE; CELL ISOLATION; CLINICAL ARTICLE; CLINICAL OUTCOME; CUTANEOUS MELANOMA; FEMALE; GENE MUTATION; GENE SEQUENCE; HUMAN; HUMAN CELL; HUMAN TISSUE; LASER CAPTURE MICRODISSECTION; MALE; MELANOMA CELL LINE; MUTATION RATE; ONCOGENE; ONCOGENE B RAF KINASE; ONCOGENE KIT; ONCOGENE N RAS; PARANASAL SINUS CANCER; PRIORITY JOURNAL; PROMOTER REGION; SINGLE NUCLEOTIDE POLYMORPHISM; SINONASAL MALIGNANT MELANOMA; TUMOR GROWTH; CANCER STAGING; COHORT ANALYSIS; GENETIC ASSOCIATION STUDY; GENETICS; MELANOMA; METABOLISM; MIDDLE AGED; MUTATION; NOSE MUCOSA; NOSE TUMOR; PARANASAL SINUS; PARANASAL SINUS TUMOR; PATHOLOGY; REGISTER; SWEDEN; VERY ELDERLY;

AGED; AGED, 80 AND OVER; COHORT STUDIES; FEMALE; GENETIC ASSOCIATION STUDIES; HUMANS; MALE; MELANOMA; MIDDLE AGED; MUTATION; NASAL MUCOSA; NEOPLASM PROTEINS; NEOPLASM STAGING; NOSE NEOPLASMS; PARANASAL SINUS NEOPLASMS; PARANASAL SINUSES; PROMOTER REGIONS, GENETIC; REGISTRIES; SWEDEN; TELOMERASE;

EID: 84983509382     PISSN: 09608931     EISSN: 14735636     Source Type: Journal    
DOI: 10.1097/CMR.0000000000000148     Document Type: Article

References (29)

1. Clifton N, Harrison L, Bradley PJ, Jones NS. Malignant melanoma of nasal cavity and paranasal sinuses: report of 24 patients and literature review. J Laryngol Otol 2011; 125:479-485.
2. Harbo G, Grau C, Bundgaard T, Overgaard M, Elbrond O, Sogaard H, Overgaard J. Cancer of the nasal cavity and paranasal sinuses. A clinico-pathological study of 277 patients. Acta Oncol 1997; 36:45-50.
3. Norlander T, Frodin JE, Silfversward C, Anggard A. Decreasing incidence of malignant tumors of the paranasal sinuses in Sweden. An analysis of 141 consecutive cases at Karolinska Hospital from 1960 to 1980. Ann Otol Rhinol Laryngol 2003; 112:236-241.
4. Jethanamest D, Vila PM, Sikora AG, Morris LG. Predictors of survival in mucosal melanoma of the head and neck. Ann Surg Oncol 2011; 18:2748-2756.
5. Jangard M, Hansson J, Ragnarsson-Olding B. Primary sinonasal malignant melanoma: a nationwide study of the Swedish population, 1960-2000. Rhinology 2013; 51:22-30.
6. Turner JH, Reh DD. Incidence and survival in patients with sinonasal cancer: a historical analysis of population-based data. Head Neck 2012; 34:877-885.
7. Lund VJ, Chisholm EJ, Howard DJ, Wei WI. Sinonasal malignant melanoma: an analysis of 115 cases assessing outcomes of surgery, postoperative radiotherapy and endoscopic resection. Rhinology 2012; 50:203-210.
8. Bradley PJ. Primary malignant mucosal melanoma of the head and neck. Curr Opin Otolaryngol Head Neck Surg 2006; 14:100-104.
9. Moreno MA, Roberts DB, Kupferman ME, deMonte F, El-Naggar AK, Williams M, et al. Mucosal melanoma of the nose and paranasal sinuses, a contemporary experience from the M. D. Anderson Cancer Center. Cancer 2010; 116:2215-2223.
10. Gandini S, Sera F, Cattaruzza MS, Pasquini P, Picconi O, Boyle P, Melchi CF. Meta-analysis of risk factors for cutaneous melanoma: II. Sun exposure. Eur J Cancer 2005; 41:45-60.
11. Zebary A, Jangard M, Omholt K, Ragnarsson-Olding B, Hansson J. KIT, NRAS and BRAF mutations in sinonasal mucosal melanoma: a study of 56 cases. Br J Cancer 2013; 109:559-564.
12. Carvajal RD, Antonescu CR, Wolchok JD, Chapman PB, Roman RA, Teitcher J, et al. KIT as a therapeutic target in metastatic melanoma. JAMA 2011; 305:2327-2334.
13. Davies H, Bignell GR, Cox C, Stephens P, Edkins S, Clegg S, et al. Mutations of the BRAF gene in human cancer. Nature 2002; 417:949-954.
14. Edlundh-Rose E, Egyhazi S, Omholt K, Mansson-Brahme E, Platz A, Hansson J, Lundeberg J. NRAS and BRAF mutations in melanoma tumours in relation to clinical characteristics: a study based on mutation screening by pyrosequencing. Melanoma Res 2006; 16:471-478.
15. Lee JH, Choi JW, Kim YS. Frequencies of BRAF and NRAS mutations are different in histological types and sites of origin of cutaneous melanoma: a meta-analysis. Br J Dermatol 2011; 164:776-784.
16. Omholt K, Grafstrom E, Kanter-Lewensohn L, Hansson J, Ragnarsson-Olding BK. KIT pathway alterations in mucosal melanomas of the vulva and other sites. Clin Cancer Res 2011; 17:3933-3942.
17. Omholt K, Platz A, Kanter L, Ringborg U, Hansson J. NRAS and BRAF mutations arise early during melanoma pathogenesis and are preserved throughout tumor progression. Clin Cancer Res 2003; 9:6483-6488.
18. Zebary A, Omholt K, Vassilaki I, Hoiom V, Linden D, Viberg L, et al. KIT, NRAS, BRAF and PTEN mutations in a sample of Swedish patients with acral lentiginous melanoma. J Dermatol Sci 2013; 72:284-289.
19. Cong YS, Wen J, Bacchetti S. The human telomerase catalytic subunit hTERT: organization of the gene and characterization of the promoter. Hum Mol Genet 1999; 8:137-142.
20. Daniel M, Peek GW, Tollefsbol TO. Regulation of the human catalytic subunit of telomerase (hTERT). Gene 2012; 498:135-146.
21. Hanahan D, Weinberg RA. Hallmarks of cancer: the next generation. Cell 2011; 144:646-674.
22. Mukherjee S, Firpo EJ, Wang Y, Roberts JM. Separation of telomerase functions by reverse genetics. Proc Natl Acad Sci USA 2011; 108: E1363-E1371.
23. Horn S, Figl A, Rachakonda PS, Fischer C, Sucker A, Gast A, et al. TERT promoter mutations in familial and sporadic melanoma. Science 2013; 339:959-961.
24. Huang FW, Hodis E, Xu MJ, Kryukov GV, Chin L, Garraway LA. Highly recurrent TERT promoter mutations in human melanoma. Science 2013; 339:957-959.
25. Ruden M, Puri N. Novel anticancer therapeutics targeting telomerase. Cancer Treat Rev 2013; 39:444-456.
26. Vogelstein B, Papadopoulos N, Velculescu VE, Zhou S, Diaz LA Jr, Kinzler KW. Cancer genome landscapes. Science 2013; 339:1546-1558.
27. Egberts F, Kruger S, Behrens HM, Bergner I, Papaspyrou G, Werner JA, et al. Melanomas of unknown primary frequently harbor TERT-promoter mutations. Melanoma Res 2014; 24:131-136.
28. Rachakonda PS, Hosen I, de Verdier PJ, Fallah M, Heidenreich B, Ryk C, et al. TERT promoter mutations in bladder cancer affect patient survival and disease recurrence through modification by a common polymorphism. Proc Natl Acad Sci USA 2013; 110:17426-17431.
29. Hsu CP, Hsu NY, Lee LW, Ko JL. Ets2 binding site single nucleotide polymorphism at the hTERT gene promoter-effect on telomerase expression and telomere length maintenance in non-small cell lung cancer. Eur J Cancer 2006; 42:1466-1474.